Characterization of two affinity matured Anti-Yersinia pestis F1 human antibodies with medical countermeasure potential.

Autor: Velappan, Nileena, Biryukov, Sergei S., Rill, Nathaniel O., Klimko, Christopher P., Rosario-Acevedo, Raysa, Shoe, Jennifer L., Hunter, Melissa, Dankmeyer, Jennifer L., Fetterer, David P., Bedinger, Daniel, Phipps, Mary E., Watt, Austin J., Abergel, Rebecca J., Dichosa, Armand, Kozimor, Stosh A., Cote, Christopher K., Lillo, Antonietta M.
Předmět:
Zdroj: PLoS ONE; 7/2/2024, Vol. 19 Issue 7, p1-22, 22p
Abstrakt: Yersinia pestis, the causative agent of plague and a biological threat agent, presents an urgent need for novel medical countermeasures due to documented cases of naturally acquired antibiotic resistance and potential person-to-person spread during a pneumonic infection. Immunotherapy has been proposed as a way to circumvent current and future antibiotic resistance. Here, we describe the development and characterization of two affinity matured human antibodies (αF1Ig AM2 and αF1Ig AM8) that promote survival of mice after exposure to aerosolized Y. pestis. We share details of the error prone PCR and yeast display technology-based affinity maturation process that we used. The resultant matured antibodies have nanomolar affinity for Y. pestis F1 antigen, are produced in high yield, and are resilient to 37°C stress for up to 6 months. Importantly, in vitro assays using a murine macrophage cell line demonstrated that αF1Ig AM2 and αF1Ig AM8 are opsonic. Even more importantly, in vivo studies using pneumonic plague mouse models showed that 100% of the mice receiving 500 μg of IgGs αF1Ig AM2 and αF1Ig AM8 survived lethal challenge with aerosolized Y. pestis CO92. Combined, these results provide evidence of the quality and robustness of αF1Ig AM2 and αF1Ig AM8 and support their development as potential medical countermeasures against plague. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje